Pharmacokinetics of NV06 in patients with advanced cancer
Completed
- Conditions
- Pharmacokinetics of a novel isoflavone, phenoxodiolPharmacokinetics of phenoxodiol after an intravenous bolus and after an intravenous infusion in patients with advanced cancerCancerCancer - Other cancer types
- Registration Number
- ACTRN12610000334000
- Lead Sponsor
- ovogen Pty Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Male or females with metastatic disease from any solid tumour, age 18 to 70 years, normal haematological parameters and the provision of signed informed consent
Exclusion Criteria
Leukemia or lymphoma, allergy to soy products, vegetarian diet or use of soy product more than three times a week, the use of sex steroids in the previous two months, antibiotic therapy within one month prior to the study period or at any time during the study, smoking of greater than 10 cigarettes/day, a prognosis of at least three months, and the known presence of central nervous system metastases, active infection or other co-morbid disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method